Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The JAK Inhibitor INCB20 Induces Antiproliferative and Apoptotic Effects in Human Myeloma Cells In Vitro and In Vivo .

Renate Burger, PhD, Steven Legouill, MD, Yu-Tzu Tai, PhD, Reshma Shringarpure, PhD, Klaus Podar, MD, PhD, Laurence Catley, MD, Pierfrancesco Tassone, MD, Paola Neri, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Eian Caulder, BS, Kris Vaddi, PhD, Claire L. Neilan, PhD, Martin Gramatzki, MD, Jordan S. Fridman, PhD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 3357.

https://doi.org/10.1182/blood.V106.11.3357.3357

Published: 2005

Journal Articles

Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).

Klaus Podar, MD, PhD, Reshma Shringarpure, PhD, Yu-Tzu Tai, PhD, Melissa Simoncini, BS, Martin Sattler, PhD, Kenji Ishitsuka, MD, PhD, Paul G. Richardson, MD, Teru Hideshima, MD, PhD, Dharminder Chauhan, JD, PhD, Anderson C. Kenneth, MD

Blood (2004) 104 (11): 2453.

https://doi.org/10.1182/blood.V104.11.2453.2453

Published: 2004

Journal Articles

Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.

Reshma Shringarpure, PhD, Deepak Bhole, PhD, Renate Burger, PhD, Laurence Catley, MBBS, FRACP, FRCPA, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Constantine Mitsiades, MD, PhD, Nikhil C. Munshi, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, PhD

Blood (2004) 104 (11): 285.

https://doi.org/10.1182/blood.V104.11.285.285

Published: 2004

Journal Articles

JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.

Laurence Catley, MBBS, FRACP, FRCPA, Yu-Tzu Tai, PhD, Reshma Shringarpure, PhD, Renate Burger, PhD, Moni Son, Klaus Podar, MD, PhD, Dharminder Chauhan, PhD, Teru Hideshima, MD, PhD, Louis Denis, MD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3413.

https://doi.org/10.1182/blood.V104.11.3413.3413

Published: 2004

Journal Articles

NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors.

Nicholas Mitsiades, MD, PhD, Ciaran J. McMullan, Vassiliki Poulaki, MD, PhD, Reshma Shringarpure, PhD, Towia A. Libermann, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Robert L. Schlossman, MD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, PhD, Carlos Garcia-Echeverria, PhD, Francesco Hoffmann, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2004) 104 (11): 766.

https://doi.org/10.1182/blood.V104.11.766.766

Published: 2004

Journal Articles

Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.

Blood (2004) 104 (11): 644.

https://doi.org/10.1182/blood.V104.11.644.644

Published: 2004

NARROW

The JAK Inhibitor INCB20 Induces Antiproliferative and Apoptotic Effects in Human Myeloma Cells In Vitro and In Vivo .

Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).

Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.

JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.

NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors.

Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

The JAK Inhibitor INCB20 Induces Antiproliferative and Apoptotic Effects in Human Myeloma Cells In Vitro and In Vivo .

Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®).

Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.

JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.

NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors.

Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only